Jonathan R Honegger1,2,3, Charitha Gowda1,2,4. 1. Division of Pediatric Infectious Diseases, Nationwide Children's Hospital. 2. Department of Pediatrics, The Ohio State University College of Medicine. 3. Center for Vaccines and Immunity, Abigail Wexner Research Institute. 4. Partners for Kids, Nationwide Children's Hospital, Columbus, Ohio, USA.
Abstract
PURPOSE OF REVIEW: Direct-acting antiviral (DAA) regimens targeting hepatitis C virus (HCV) are now approved for young children. This review examines recent DAA experience in children, current treatment recommendations and challenges, and potential treatment-as-prevention strategies. RECENT FINDINGS: In 2021, the US FDA extended approval of two pan-genotypic DAA regimens, glecaprevir/pibrentasvir and sofosbuvir/velpatasvir, to children as young as age 3 years based on high success rates and reassuring safety profiles in registry trials. Similar performance has been replicated with real-world DAA use in thousands of adolescents and in limited reports of children with high-risk conditions, including cirrhosis, cancer, thalassemia and HIV-coinfection. Treatment without delay is now recommended in the USA for viremic children aged 3 years and up to prevent disease progression and future spread. To date, treatment expansion is limited by high rates of undiagnosed paediatric infection. Universal prenatal screening will aid identification of perinatally exposed newborns, but new strategies are needed to boost testing of exposed infants and at-risk adolescents. Postpartum treatment programmes can prevent subsequent vertical transmission but are hampered by low rates of linkage to care and treatment completion. These challenges may be avoided by DAA use in pregnancy, and this warrants continued study. SUMMARY: Paediatric HCV is now readily curable. Substantial clinical and public health effort is required to ensure widespread uptake of this therapeutic breakthrough.
PURPOSE OF REVIEW: Direct-acting antiviral (DAA) regimens targeting hepatitis C virus (HCV) are now approved for young children. This review examines recent DAA experience in children, current treatment recommendations and challenges, and potential treatment-as-prevention strategies. RECENT FINDINGS: In 2021, the US FDA extended approval of two pan-genotypic DAA regimens, glecaprevir/pibrentasvir and sofosbuvir/velpatasvir, to children as young as age 3 years based on high success rates and reassuring safety profiles in registry trials. Similar performance has been replicated with real-world DAA use in thousands of adolescents and in limited reports of children with high-risk conditions, including cirrhosis, cancer, thalassemia and HIV-coinfection. Treatment without delay is now recommended in the USA for viremic children aged 3 years and up to prevent disease progression and future spread. To date, treatment expansion is limited by high rates of undiagnosed paediatric infection. Universal prenatal screening will aid identification of perinatally exposed newborns, but new strategies are needed to boost testing of exposed infants and at-risk adolescents. Postpartum treatment programmes can prevent subsequent vertical transmission but are hampered by low rates of linkage to care and treatment completion. These challenges may be avoided by DAA use in pregnancy, and this warrants continued study. SUMMARY: Paediatric HCV is now readily curable. Substantial clinical and public health effort is required to ensure widespread uptake of this therapeutic breakthrough.
Authors: Rachel L Epstein; Jianing Wang; Liesl Hagan; Kenneth H Mayer; Jon Puro; Benjamin P Linas; Sabrina A Assoumou Journal: JAMA Date: 2019-12-10 Impact factor: 56.272
Authors: Marian Jarlenski; Qingwen Chen; Katherine A Ahrens; Lindsay Allen; Anna E Austin; Catherine Chappell; Julie M Donohue; Lindsay Hammerslag; Paul Lanier; Mary Joan McDuffie; Jeffrey Talbert; Lu Tang; Elizabeth E Krans Journal: Obstet Gynecol Date: 2022-04-05 Impact factor: 7.623
Authors: Rachel L Epstein; Carole Moloney; Jacob Garfinkel; Kelley Saia; Elisha M Wachman; Sara Lodi; Stephen I Pelton Journal: Hepatol Commun Date: 2021-07-01
Authors: Maureen M Jonas; Susan Rhee; Deirdre A Kelly; Antonio Del Valle-Segarra; Cornelia Feiterna-Sperling; Susan Gilmour; Regino P Gonzalez-Peralta; Loreto Hierro; Daniel H Leung; Simon C Ling; Yuri Lobzin; Steven Lobritto; Tatsuki Mizuochi; Michael R Narkewicz; Vishakha Sabharwal; Jessica Wen; Hoi Kei Lon; John Marcinak; Andrew Topp; Rakesh Tripathi; Etienne Sokal Journal: Hepatology Date: 2021-07 Impact factor: 17.425